ArticleJCO oncology practice2026
Prescription Monitoring Program Mandates and Opioids Dispensed to Patients Dying of Cancer.
Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeState legislations mandating prescriber use of Prescription Drug Monitoring Programs (PDMPs) may have the unintended consequence of restricting opioid analgesics to patients dying of cancer. This study aims to assess associations of comprehensive PDMP mandates with opioid-related outcomes for patients dying of cancer, overall and by decedent race and ethnicity.
methodsStudy population were Medicare decedents who were age 66 years or older, diagnosed with breast, colorectal, lung, or prostate cancer, and died of cancer in 2011-2019. This cross-sectional study used SEER-Medicare data and a difference-in-differences design. Study sample included decedents from 10 states with an operating PDMP on January 1, 2011. Outcomes included the dichotomous event of having one or more opioid days, total and daily morphine milligram equivalents (MMEs) if having opioids, near the end of life. Generalized linear models were estimated for dichotomous (logit link function) and continuous (log) outcomes.
resultsThis study included 115,256 decedents. Comprehensive PDMP mandates were associated with modest reductions in the rate of one or more opioid days (from 45.1% to 43.9%, difference = 0.011 [95% CI, -0.019 to -0.003]), total dose (from 1,600.6 to 1,521.0 MMEs, difference = 79.6 [95% CI, -131.5 to -27.6]), and daily dose from all opioids (from 75.7 to 72.9 MMEs, difference = 2.7 [95% CI, -5.1 to -0.4]). Compared with non-Hispanic White decedents, Black decedents experienced a four-fold reduction, and Asian/Pacific Islander decedents experienced a two-fold reduction, in the rate of one or more opioid days.
conclusionComprehensive PDMP mandates were associated with modest reductions in opioid analgesics dispensed to Medicare patients dying of cancer. Non-Hispanic Black and Asian/Pacific Islander decedents experienced larger reductions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.